Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nezastomig + cemiplimab
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Nezastomig + cemiplimab is an investigational combination immunotherapy being developed by Regeneron Pharmaceuticals and Bayer. The combination consists of nezastomig (REGN5678), a first-in-class bispecific antibody that targets prostate-specific membrane antigen (PSMA) and CD28, and cemiplimab, a monoclonal antibody targeting programmed cell death protein 1 (PD-1). Nezastomig provides a co-stimulatory signal to T-cells by bridging PSMA-expressing tumor cells and CD28 on T-cells, while cemiplimab blocks the PD-1/PD-L1 inhibitory pathway. This dual approach is designed to enhance anti-tumor T-cell activation and proliferation, particularly in patients with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC).
- Brand names
- Libtayo
- Other names
- REGN5678 + cemiplimabnezastomig plus cemiplimabREGN5678 + REGN2810
02
Targets
CD28 (Cluster of Differentiation 28)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on nezastomig + cemiplimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nezastomig + cemiplimab.